In a move that could reshape how doctors approach both weight and heart health, the American College of Cardiology (ACC) ...

Copenhagen, Denmark Friday, June 20, 2025, 15:00 Hrs [IST] ...

Company announcement - No. 15 / 2025 Zealand Pharma announces positive topline results from 28-week Phase 1b trial with GLP-1/GLP-2 receptor dual agonist dapiglutide Body weight reductions of a mean ...

Infection, delayed kidney function, kidney loss and death are all risks associated with kidney transplant surgery in obese ...

They were designed to treat diabetes, then prescribed for weight loss, and now—as researchers are finding—they might hold the ...

The Gut Gummy™ is a new affiliate division of Beyond Slim®, created to bring next-gen gut health to the forefront of everyday ...

As snacking continues to evolve from a mindless indulgence to a more functional and intentional activity, economic and health pressures are reshaping how consumers approach the snack aisle according ...

A 68-week phase 3 trial found that coadministered cagrilintide and semaglutide led to significant and clinically meaningful ...

Treatments designed to help patients preserve muscle while losing weight with popular obesity drugs by Eli Lilly and Novo ...

On May 29, 2025, Professor Sun Jinpeng's team and Professor Yu Xiao's team at Shandong University, collaborating with Professor Jiang Changtao from Peking University, Professor Pang Yanli, and ...